Strike CEO Jack Mallers’ Bold Prediction: Bitcoin as the Future Dominant Store of Value or Jack Mallers, Strike CEO: Bitcoin to Rule as the Preeminent Store of Value?

Bitcoin’s Soaring Potential as a Global Store of Value: A Charming Conversation with Strike CEO Jack Mallers Once upon a time in the enchanted land of cryptocurrencies, there lived a charismatic CEO named Jack Mallers. He was the proud leader of Strike, a fintech company that aimed to make Bitcoin (BTC) the preferred currency for…

Read More

FTAI Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Announces Investigation into Potential Securities Law Violations

Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against FTAI Aviation Ltd. New York, NY – In a significant development for investors, Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, has announced the filing of a class action lawsuit against FTAI Aviation Ltd. (“FTAI Aviation” or “the Company”) (NASDAQ: FTAI) and certain of…

Read More

“FRMO Corporation’s Q2 2025 Earnings Call: A Comprehensive Recap”

FRMO Corporation (OTCPK:FRMO) Q2 2025 Earnings Conference Call Overview Company Participants Thérèse Byars – Corporate Secretary Murray Stahl – Chairman & Chief Executive Officer Conference Call Participants Thérèse Byars Good afternoon, everyone. This is Thérèse Byars speaking, and I’m the Corporate Secretary of FRMO Corp. Thank you for joining us on this call. Today, we…

Read More

First Patient Enrolled in BioPorto’s US Study of ProNephro AKI NGAL for Adult Use at Massachusetts General Hospital

October 29, 2024 Announcement no. 20 First Patient In – BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital COPENHAGEN, Denmark and BOSTON, MA, USA, October 29, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the…

Read More

Actinium Pharma’s Game-Changing Triple Therapy: Actimab-A with Venetoclax and Astx-727 Starts NCI-Supported Clinical Trial for Newly Diagnosed AML

Actinium Pharmaceuticals Initiates First Clinical Trial for Actimab-A Triplet Combination in AML Actinium Pharmaceuticals, a trailblazer in the field of targeted radiotherapies, has announced the initiation of a new clinical trial under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). This trial, identified by the number NCT06802523, will explore the…

Read More

Get Ready to Rock Your Finances: MRC Global Takes Bold Steps to Boost Capital Structure!

Exciting News for MRC Global Inc. Agrees to Repurchase Preferred Stock Launching Term Loan B Financing and Pursuing Amendment to ABL Facility It’s always a great feeling when a company you’ve invested in announces positive news that will benefit both the company and its shareholders. MRC Global Inc. recently made headlines by agreeing to repurchase…

Read More